Euronext

Sartorius Stedim Biotech releases Universal Registration Document 2023

Retrieved on: 
Friday, February 16, 2024

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.

Key Points: 
  • Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech: Information on Document Availability

Retrieved on: 
Friday, February 16, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:
    It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2023
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Retrieved on: 
Thursday, February 15, 2024

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Key Points: 
  • Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
    Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close.
  • Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
  • A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 2023 earnings call webcast .
  • If you plan to ask a question, please use the following link: Nyxoah’s Q4 2023 earnings call .

Galapagos presents at EBMT-EHA annual meeting 2024

Retrieved on: 
Thursday, February 15, 2024

Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.

Key Points: 
  • Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.
  • Further, previously disclosed safety, efficacy and feasibility data from EUPLAGIA-1 and ATALANTA-1 support the potential of Galapagos’ innovative approach to CAR-T manufacturing and of the transformational impact on patients with severe hematologic cancers.
  • “At Galapagos, we are committed to accelerating transformative innovation to address the unmet needs of patients with advanced cancers, and the data we are presenting today demonstrates our positive momentum toward this goal,” said Dr Jeevan Shetty, M.D., Head of Clinical Development Oncology at Galapagos.
  • Moreover, the abundance of both CD4+ and CD8+ TN/SCM CAR-T cells in the final product correlated with CAR-T-cell exposure in patients.

InterDigital and Broadpeak Announce Collaboration on MPEG V3C Standardized Content Distribution At Scale

Retrieved on: 
Tuesday, February 13, 2024

Volumetric video is a critical component in the creation and enjoyment of increasingly immersive experiences and the MPEG V3C standard defines the general mechanism for coding and streaming volumetric content.

Key Points: 
  • Volumetric video is a critical component in the creation and enjoyment of increasingly immersive experiences and the MPEG V3C standard defines the general mechanism for coding and streaming volumetric content.
  • The wide-scale distribution of volumetric content to broad audiences also depends on efficient and V3C-compliant distribution networks, and this is a key area of focus for the InterDigital-Broadpeak collaboration.
  • InterDigital will contribute the V3C end-to-end implementation platform built jointly with its partner Philips, and Broadpeak will contribute on packaging and content delivery network (CDN) technologies.
  • “Thanks to our collaboration with InterDigital, we will further enhance our Origin-Packager and CDN to stream standardized V3C volumetric content to wide audiences.”
    InterDigital and Broadpeak will showcase the latest results of their collaboration on immersive content distribution at scale at Mobile World Congress in Barcelona from February 26 – 29.

KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share

Retrieved on: 
Friday, February 9, 2024

EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.

Key Points: 
  • EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.
  • This is a premium of 161% to the closing price of EUR 3.83 on February 8, 2024.
  • KBC joins three other banks whose research analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price.
  • “KBC Securities’ initiation of coverage reflects strong confidence in our ability to achieve this year’s milestones, which include the planned commercialization of our ARC-EX® platform later this year,” said Dave Marver, CEO of ONWARD Medical.

ONWARD® MEDICAL ANNOUNCES PRESENTATION AT BIOCAPITAL EUROPE

Retrieved on: 
Wednesday, February 7, 2024

EINDHOVEN, the Netherlands, Feb. 07, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its participation in BioCapital Europe in Amsterdam on February 8, 2024.

Key Points: 
  • EINDHOVEN, the Netherlands, Feb. 07, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its participation in BioCapital Europe in Amsterdam on February 8, 2024.
  • The event, one of Europe’s leading life sciences investor conferences, is organized by life sciences venture capital fund EQT Life Sciences, an investor in ONWARD Medical.
  • ONWARD Medical CEO Dave Marver will present and participate in 1:1 and group meetings with investors during the conference.
  • *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting

Retrieved on: 
Wednesday, February 7, 2024

The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023.

Key Points: 
  • The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual Shareholders' Meeting to be held on March 26, 2024, to pay a dividend of 0.69 euros per share for fiscal 2023.
  • The Board of Directors also approved the decision to submit to the Annual Shareholders’ Meeting the 2023 results of Sartorius Stedim Biotech which had already been published on a preliminary basis on January 26, 2024.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Retrieved on: 
Monday, February 5, 2024

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Key Points: 
  • NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
    BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today.
  • With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader.
  • Earlier in his career, Thomas served in key leadership roles in clinical and medical assessment, business development and market access at Novartis.
  • Alan Watt, Chief Executive Officer of NodThera, said: “We are delighted to welcome Thomas to the NodThera team, with his wealth of sector experience and successful execution of drug development programs across multiple therapeutic areas.

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Retrieved on: 
Wednesday, January 31, 2024

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.

Key Points: 
  • Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.
    As previously announced, the transfer includes the entire Jyseleca® business, including the European and UK Marketing Authorizations, and the commercial, medical affairs and development activities for Jyseleca®.
  • In connection with the completion of the transaction, approximately 400 Galapagos positions in 14 European countries transferred to Alfasigma to support business continuity and ongoing patient access.
  • Michele Manto, former Chief Commercial Officer of Galapagos, also joins Alfasigma to lead the Jyseleca® business.
  • Galapagos will contribute up to €40 million to Alfasigma by June 2025 for Jyseleca® related development activities.